Why Pfizer Pushed for Transparency and Diversity in Vaccine Development - COVID-19 Clinical Trial
Breaking News | COVID-19

Why Pfizer Pushed for Transparency and Diversity in Vaccine Development

The drug company Pfizer and its German partner BioNTech announced initial late-stage vaccine data Monday. It revealed that the vaccine under development is more than 90% effective in preventing COVID-19, though the trial is still ongoing and results are not yet complete. The companies were shooting for a 60% threshold, and other experts said even a 55% effectiveness rate would have made the vaccine viable.

In the last few months, Pfizer and BioNTech have shared other details of the process including trial blueprints, the breakdown of the subjects and ethnicities, and whether they’re taking money from the government. Why transparency? Surveys suggest a high degree of public skepticism about this vaccine process. In fact, 51% of Americans said they would “definitely” or “probably” take a vaccine, according to a September poll from the Pew Research Center. That’s down from May when 72% of respondents said they would likely get one.

  • https://www.marketplace.org/2020/11/09/why-pfizer-says-it-pushed-for-transparency-and-diversity-in-vaccine-development-process/

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

 Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM™ adjuvant.

“The FDA’s decision to grant Fast Track Designation for NVX-CoV2373 reflects the urgent need for a safe and effective vaccine to prevent COVID-19, and we look forward to working closely with the agency to accelerate access to this vaccine,” said Gregory M. Glenn, M.D., President of Research and Development, Novavax. “While the regulatory review of this clinical program will be expedited, Novavax remains committed to a data-driven and scientifically rigorous approach in demonstrating safety and efficacy, which we believe will support confidence in the vaccine in the U.S. and globally.”

Share this:

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.